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with the terms “EQ-5D”, “SF-36”, “SF-12” and “SF-6D”. RESULTS: The initial search
revealed 5745 publications, 227 of which referring to the HR-QoL questionnaires, of
whom 209 were considered as relevant . Of these, 69 publications were proposed
study protocols in which 31 announced to evaluate CE as an outcome value.
Amongst the remaining 140 papers, 34 were reporting on a new technique, an
alternative questionnaire or on HR-QoL without referring to CE, and 33 were re-
porting on pharmacology or HTA. This results finally in 73 research reports regard-
ing care programs. In only 5 (7%) of them CE has been evaluated, in which 4 by
comparing direct costs and 1 by using QALY’s as outcome value. CONCLUSIONS:
While longitudinal care programs for chronically ill implicate the use of many
health care workers and labour cost is known to count heavily on the budget, CE is
until now, almost never evaluated. Although CE can obviously not be claimed to be
the single important criterion, it is a promising evolution to notice that many study
protocols in this field also aspire after this outcome value.
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OBJECTIVES: Sugammadex is registered for decurarization of moderate/deep neu-
romuscular blockade induced by rocuronium or vecuronium. The advantages com-
pared to the well-known decurarization drugs like neostigmine is that undesirable
side-effects (bradycardia-bronchoconstriction-hypersalivation-nausea-vomiting)
are avoided and deeper levels of blockade can be reversed. In Belgium its reim-
bursement is restricted to certain conditions (impossible intubation or rapid decu-
rarization of deep blockade when medically required or rapid decurarizaton mod-
erate blockade in patients with obstructions (stomach/bowel, bile duct, urinary
tract) or when administration of neostigmine is contra-indicated). The objective of
this study was to evaluate Belgian real-life use of sugammadex one year after
reimbursement was granted.METHODS: The medical records of 330 adult patients
being treated with sugammadex during the first half year of 2011 (6 hospitals se-
lecting 55 consecutive patients) were retrospectively reviewed. Data collection in-
cluded baseline patient-characteristics, hospital-, surgery- and sugammadex-re-
lated info. In addition, a 2-round expert-panel among 12 physicians was organized.
RESULTS: Based on the expert-panel (in combination with published data), it was
estimated that in Belgium rocuronium is used in about 58,100 surgical interven-
tions per year. Reversal with sugammadex is performed in 21.5% of them. Mean age
of the patients using sugammadex was 54 years (/ 17 SD), 45% of the patients
belonged to ASA (American Society of Anesthesiologists) category I-II (healthy-
mild systemic disease), 33% to categoryIII, 84% had co-morbidities. Sugammadex
is mainly used after gastroenterological surgery (53%; high contribution of bariat-
ric-surgery), followed by gynaecological interventions (12%), estimates confirmed
by the expert-panel. According to the experts, in 29% of the patients reversal with
sugammadex was used outside the reimbursement conditions. CONCLUSIONS:
The study confirms that, in Belgium, sugammadex is used when medically needed,
a substantial part being used outside the reimbursement conditions.
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OBJECTIVES: To propose a prospective payment method for the public Health Cen-
ters (HC) in Greece, based on the reimbursement method of Ambulatory Patient
Groups (APG). METHODS: In the absence of electronic patient records, imple-
mented International Classification of Diseases and Current Procedural Terminol-
ogy coding systems, an updated costing system and given that HC in Greece pro-
vide a quite low bundle of services the methodology of the study was accordingly
adjusted. The services provided by the HC were grouped and classified in a few
distinct groups and evaluated by a Delphi panel according to their usability, coher-
ence and technology and labor resource use. According to each groups resource
use, a corresponding labor and technology weight was estimated. An expert panel
estimated the percentage contribution of labor and technology cost in the payment
of each group. The average cost of visit in the HC was used as a base rate. A
mathematical model employed these parameters and provided an estimation of
each group’s payment. Model’s results and parameters were evaluated and ad-
justed to a second expert panel recommendations. APGs’ packaging and discount-
ing techniques were applied. RESULTS: Sixteen groups were created and priced as
follows: Emergency Management (102.6€), Acute Case Management (64.7€), Follow up/
Revisit for an urgent/emergency problem (29.5€), Complete Health Evaluation (48.1€),
Partial Health Evaluation (39.6€), Regular consultation of healthy individual (34.9€),
Laboratory tests (100.8€), Prescription/simple repetition (4.7€), Prescription of drugs/
laboratory tests with Basic medical exam (18.7€), Simple diagnostic/therapeutic pro-
cedure (26.9€), Complex diagnostic/therapeutic procedure (57.6€), Immunization
(23.5€), Primary Prevention/Health education (24.7€), Complex preventive procedure
(39.8€), Physical medicine/Rehabilitation/Counseling/Psychotherapy/Social support
consultation (29.1€), Administrative procedure (12.8€). CONCLUSIONS: Despite the
limitation imposed by the health system’s infrastructure, the current study is es-
timated that can provide a viable reimbursement method and a starting point for
the development of a more detailed method in the future.
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OBJECTIVES: Describe and analyze recent changes in the French drug market ac-
cess in which a dramatic shift in practice is undergoing and impacted by two laws
entered into force in December 2011. METHODS: Literature review was performed
to provide core understanding of the current and future trends in French drug
market access to anticipate its impact for pharmaceutical industry. RESULTS: Con-
dition severity used to be main driver of reimbursement level is now replaced by
drug efficacy criterion. Moreover, the effect size requested for acknowledging drug
innovation has substantially increased. Perceived evidence might also be more
important than actual evidence. Currently, the French National Authority (HAS) is
working on a new therapeutic index that will drive the pricing and reimbursement.
Comparative evidence and real world data are pointed as critical, conditioning
marketing authorization, and will be increasingly requested at the light of the new
drug safety law n.2011-2012. Moreover, within this new legal framework there is a
reinforcement of the regulation about conflicts of interest, a much closed regula-
tion of off-label prescription and early entry of drugs as well as a wide promotion of
generic drugs. The new social security funding law n.2011-1906 pursues the cost
containment measures to control health insurance expenses. This law includes the
Economic and Public Health Assessment Committee (CEESP) in the social security
code. CEESP, that will operate independently of the Transparency Committee, is in
charge of health economics evaluation to determine the most efficient therapeutic
strategies and edit recommendations for decision makers. CONCLUSIONS: French
drug market access will be more and more driven by comparative cost-effective-
ness data and post-marketing studies. Companies will need to anticipate these
requirements during the drug development. However in France, there exists little
or no culture of using health economics for decision making and rather resistance
to it.
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OBJECTIVES: Pricing regulation in Japan is thought to be conservative, however
over the last years, an acceleration of pricing regulation changes has occurred. We
propose to review the dramatic pricing regulation changes that have occurred
especially in 2012. METHODS: Collection and analyses of changes have been per-
formed through literature review of public sources and key opinion leader’s
interviews. RESULTS: One of the main changes concerns pediatric indication that
will now induce premium price for drugs from 5% to 20%, conditional to substantial
efforts from pharmaceutical companies, including studies in Japan and pediatric
formulations. Then, usual cost plus calculation, using the last year as reference for
production, labor, distribution costs etc., will now use the average of the previous 3
years to minimize inflation. International reference pricing have been reviewed to
minimize the cost impact on NHS. As for generics, although they doubled in vol-
ume and value over the last 10 years, they progress slowly: in 2011, generic market
was 23% in volume and 9.5% in value. To counter this, doctors are now eligible for
generic prescription incentive and high co-payment on brand appears to be the
way forward to support generic uptake. Prescription form has been reviewed to
ease request for generic substitution. Generics are priced between 30% discount
down to 46% discount at the maximum. In parallel, enantiomer drugs will now be
discounted by 20% over racemates. This will put them close to generic price (30%
discount). However, opportunities for re-pricing up products were closed to pre-
vent orphan drugs from expanding indication market size and later revenue. Fi-
nally, high drug costs will be excluded from reimbursement through a process
based on drug price distribution to secure convergence toward mean price.
CONCLUSIONS:Despite apparent peace and resistance to changes, Japan market is
also undergoing dramatic changes.
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OBJECTIVES: Radiologists claim that performing two or more CT scans in succes-
sion is rarely necessary, yet the practice of multiple CT scanning during the same
visit has continued in recent years. The objective of this study is to review the
evidence and identify factors contributing to this practice. METHODS: The retro-
spective study included patients from the US Medicare 2009 hospital database.
Over 6 million outpatient claims with the following information were extracted:
patient demographics, hospital characteristics, CT scans hospital charges and
body parts associated with CT scan administration. Multi-level logistic mixed ef-
fects regression was conducted to identify significant factors associated with the
overuse of CT scans among US hospitals. RESULTS: There were 690,643 Medicare
patients that received multiple CT scans during a hospital outpatient visit in 2009.
More than 664 hospitals that administered at least two scans on more than 30% of
their Medicare outpatients. The national average was 5.4%. The figures show wide
variation among states as well, from about 5% in Maryland to almost 23% in Okla-
homa. After multivariable adjustment, female patients had a lower incidence rate
of CT scan overuse (odds ratio, 0.850; 95% CI, 0.847 to 0.851, p0.0001). Rural hos-
pitals tend to practice more CT scan overuse (odds ratio, 1.835; 95% CI, 1.670 to
2.016, p0.0001) than urban hospitals. Hospital charged patient costs of CT scans
also tend to vary across regions. CONCLUSIONS: There is strong statistical evi-
dence that US hospitals practice of CT scan overuse continued in 2009 based on the
Medicare outpatient population. While the study is subject to limitations, it cor-
roborates with previous policy studies that hospitals can and should do more to
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